ACW

Healthcare & BiotechUPTREND

$0.042

as of 2026-07-27

Who's been buying — 30 days

net $, conviction-weighted

RetailRetail · context+$422k

WAWealth & advisers+$323k

NIBInvestment banks+$251k

ResResource specialists+$218k

MMMarket makers+$54k

5d return

+0.0%

20d return

+35.5%

60d return

-8.7%

RSI 14

66.7

vs 52w high

-40.0%

vs 52w low

+82.6%

SMA 20

Above

SMA 50

Above

Price · Volume · Broker flow

Markers = announcements (red triangle = price-sensitive). Volume amber = ≥2× ADV spike. Flow bars stacked per broker group. Flow lags T+3.

Loading chart…

Closest correlates

Pearson r on log returns, window: 42d

Announcements — last 30 days

2026-07-20PSotherXanamem depression trial published in British J Psychiatry
Xanamem demonstrated statistically significant antidepressant activity in treatment-resistant MDD with cognitive impairment in a Phase 2a proof-of-concept, with benefit lagging (Week 10 peak) but consistent with cortisol-related mechanism; no cognition benefit observed, though drug was safe and well-tolerated. Publication in a leading psychiatry journal validates the mechanism and supports continued development pending funding and partnerships, with topline Alzheimer's results expected November 2026.
2026-07-13ACW AAIC poster presentation of XanaMIA trial baseline data
2026-07-08ACW senior management presentation at AAIC & internationally